Form 4: Eloxx Pharmaceuticals Director Alan Walts Exercises Stock Options

Director Alan Walts of Eloxx Pharmaceuticals exercised stock options and received restricted stock units, resulting in a change in his beneficial ownership of the company's stock.

Summary

• Alan Walts, a director at Eloxx Pharmaceuticals, executed a transaction involving the company's stock on January 24, 2025.
• He acquired 3,750 shares of common stock through the exercise of restricted stock units (RSUs).
• The exercise price for these RSUs was $0.
• Following the transaction, Mr. Walts directly owns 3,750 shares of common stock and 16,692 shares of common stock were disposed of.
• The restricted stock units vest over three years, with 50% vesting on the first anniversary of January 24, 2024, and the remaining 50% vesting in two equal annual installments thereafter, contingent on his continued service to the company.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock transactions by a company director. It does not contain any information that would indicate a positive or negative sentiment.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who have transactions involving their company's stock. It is a routine disclosure and does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors and executives in publicly traded companies, including those in the pharmaceutical industry.
• The vesting schedule of the RSUs is typical, with vesting occurring over a period of years to incentivize long-term commitment.
• The $0 exercise price is standard for RSUs, as they are granted as compensation rather than purchased.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it changes the ownership structure slightly.
• The transaction does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Eloxx Pharmaceuticals, Alan Walts, stock options, restricted stock units, beneficial ownership, insider trading, equity